Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma - Concepedia

Concepedia

Publication | Open Access

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

DOI Full Paper Access

126

Citations

19

References

2012

Year

Dmitry Nosov, Brooke Esteves, Oleg Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju Titus Chacko, Dinesh Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava

Journal of Clinical Oncology

Abstract

Tivozanib was active and well tolerated in patients with advanced RCC. These data support additional development of tivozanib in advanced RCC.

References

	Year	Citations

Page 1